{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77","upperLimit":"95.1","value":"87.5"},{"groupId":"OG001","lowerLimit":"86.2","upperLimit":"99.5","value":"95"}]}],"title":"100 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.7","upperLimit":"96.9","value":"90"},{"groupId":"OG001","lowerLimit":"86.2","upperLimit":"99.5","value":"95"}]}],"title":"365 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Achieving a platelet count ≥ 20,000/μL for 3 consecutive laboratory values on different days (with no platelet transfusions in the preceding seven days). A cumulative incidence will be computed along with a 90% CI.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days and 365 days post transplant","title":"Cumulative Incidence of Platelet Recovery","type":"SECONDARY","unitOfMeasure":"percentage of participants"}